Net Interest Margin

A new report shows the carbon removal market has the tools to fight climate change, but widespread corporate inaction threatens to strand vital projects.

Fresh off a strategic rebrand and a record-breaking year, Potomac Bancshares is courting investors and cementing its role as a Mid-Atlantic banking leader.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

A spike in layoffs to 14-year highs clashes with extreme investor optimism, raising fears of a major market correction on the horizon for 2026.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

A new bond issue strengthens Agilyx's finances, funding a dual strategy focused on immediate earnings and long-term tech licensing in plastic recycling.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

A new report reveals a grim reality: the typical American worker has under $1,000 for retirement. Is the system, not the saver, fundamentally broken?

IUOE Local 150 backs Speaker Welch for State Central Committeeperson, signaling a major power play in Illinois Democratic politics post-Danny Davis.

As EQB prepares to release its Q1 2026 results, investors are watching to see if its digital strategy and PC Financial deal can fuel a rebound.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

The firm's assets grew on market gains, but significant client outflows and shrinking fees triggered a sharp stock drop, revealing key industry pressures.

Automotive seating giant Adient boosts its 2026 forecast, banking on strong North American production and operational gains, despite a reported net loss.

Atlanticus Holdings Corp. confirms its quarterly preferred stock dividend, highlighting a rare blend of FinTech innovation with reliable investor returns.

As PHINIA preps for its NYSE Investor Day, it plans to prove its value by balancing legacy engine tech with bold investments in a lower-carbon future.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.